Stability of plasmid and viral banks supporting the cGMP manufacture of Q-Griffithsin from a TMV-based viral vector.

Autor: Corman JM; Center for Predictive Medicine, University of Louisville School of Medicine, Louisville KY, USA., Hamorsky KT; James Graham Brown Cancer Center, University of Louisville School of Medicine,Louisville KY, USA; Center for Predictive Medicine, University of Louisville School of Medicine, Louisville KY, USA; Department of Medicine, University of Louisville School of Medicine, Louisville KY, USA., Shepherd JW; Kentucky Bioprocessing Inc., Owensboro, KY, USA., Hiatt E; R.J. Reynolds Tobacco Co., Winston-Salem, NC, USA., Fuqua JL; James Graham Brown Cancer Center, University of Louisville School of Medicine,Louisville KY, USA; Center for Predictive Medicine, University of Louisville School of Medicine, Louisville KY, USA; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville KY, USA. Electronic address: j.fuqua@louisville.edu., Palmer KE; James Graham Brown Cancer Center, University of Louisville School of Medicine,Louisville KY, USA; Center for Predictive Medicine, University of Louisville School of Medicine, Louisville KY, USA; Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville KY, USA.
Jazyk: angličtina
Zdroj: Journal of biotechnology [J Biotechnol] 2020 Aug 20; Vol. 320, pp. 74-76. Date of Electronic Publication: 2020 Jun 15.
DOI: 10.1016/j.jbiotec.2020.06.009
Abstrakt: The "whole genome" TMV-based expression system, Geneware®, was used in the cGMP production of the plant-made pharmaceutical Q-Griffithsin and demonstrates stable expression for up to a two-year period. Virion and plasmid banks which contained viral cDNA and a Q-Griffithsin sequence were able to produce >200 g of Q-Griffithsin. Data assessing the quality and stability of the product banks were measured through functional assessments of visual symptomology and product expression.
Competing Interests: Declaration of Competing Interest KEP, JLF, and KTH are inventors on patents and patent applications that claim Q-GRFT composition and utility. In addition, KEP, JLF, and KTH are founders and equity holders in GROW Biomedicine LLC, which is commercializing Q-GRFT. EH, JMC, JWS declare no conflicts of interest.
(Copyright © 2020 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: